T-CURX

We envision a future in which the curative potential of CAR-T therapies can benefit many more cancer patients – without the cost and complexity of conventional viral cell manufacturing.

Health and bio Manufacturing and industrial

Latest funding

$20M Series A · December 17, 2025

Source: t-curx.com

Funding history ↓

Website: t-curx.com.

LinkedIn: linkedin.com.

Categories: Health and bio Manufacturing and industrial.

Sectors: Biotechnology, Chemical, Oncology.

Stage: Series A.

Based in: Würzburg, Germany.

Last round: Dec 17, 2025 · 330 days ago.

On Recent Funding since: Nov 8, 2026.

Signals

Website registeredAug 27, 2016 (10 years old)

Funding rounds

December 17, 2025
Series A · $20M
Source: t-curx.com
August 27, 2016
Website created

Founders and team

CR
Christoph Rader Founder
MH
Michael Hudecek Chief Medical Officer & Co-Founder

source: t-curx.com
UG
Ulf Grawunder Chief Executive Officer & Co-Founder

source: t-curx.com

Investors

Companies like T-CURX

KKaliVir Immunotherapeutics$14M Series A · Aug 2026
UUmoja Biopharma$100M Series B+ · Jan 2025
AArtios Pharma$115M Series B+ · Nov 2025
AARTBIO$132M Series B+ · Jul 2025
CClaris Bio$118M Series B+ · Jul 2026
OOri Biotech$100M Series B+ · Jan 2022

Sources and API

Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/t-curx (get a free API key).